Xanthine Oxidase Inhibition Attenuates Ischemic-Reperfusion Lung Injury

MARTIN J. LYNN, M.D., CYRIL M. GRUM, M.D., KIM P. GALLAGHER, PH.D., STEVEN F. BOLLING, M.D., G. MICHAEL DEEB, M.D., AND MELVIN L. MORGANROTH, M.D.

Pulmonary and Critical Care Division, Department of Internal Medicine, Department of Physiology, and Section of Thoracic Surgery, Department of Surgery, University of Michigan Hospitals, Ann Arbor, Michigan 48109

Presented at the Annual Meeting of the Association for Academic Surgery, Orlando, Florida, November 1-4, 1987

Ischemic-reperfusion lung injury is a factor potentially limiting the usefulness of distant organ procurement for heart–lung transplantation. Toxic oxygen metabolites are considered a major etiologic factor in reperfusion injury. Although oxygen-free radicals may be generated by many mechanisms, we investigated the role of xanthine oxidase in this injury process by using lodoxamide, a xanthine oxidase inhibitor, to inhibit ischemic-reperfusion injury in an isolated rat lung model. Isolated rat lungs were perfused with physiologic salt solution (PSS) osmotically stabilized with Ficoll until circulating blood elements were nondetectable in the pulmonary venous effluent. Lungs were rendered ischemic by interrupting ventilation and perfusion for 2 hr at 37°C. After the ischemic interval, the lungs were reperfused with whole blood and lung injury was determined by measuring the accumulation of 125I-bovine serum albumin in lung parenchyma and alveolar lavage fluid as well as by gravimetric measurements. Lung effluent was collected immediately pre- and postischemia for analysis of uric acid by high-pressure liquid chromatography. Lodoxamide (1 mM) caused significant attenuation of postischemic lung injury. Uric acid levels in the lung effluent confirmed inhibition of xanthine oxidase. Protection from injury was not complete, however, implying that additional mechanisms may contribute to ischemic–reperfusion injury in the lung.

INTRODUCTION

The inability to adequately preserve lungs for transport is a major impediment to wide clinical use of heart–lung transplantation [7]. Contributing to the problem of lung preservation is reperfusion injury which may be superimposed on any ischemic damage affecting transplanted lungs. In contrast to other organ systems, little work has been done to elucidate the mechanism of reperfusion injury in the lung following an episode of ischemia. Data from other models suggest that toxic oxygen metabolites play a role in the mechanism of ischemic–reperfusion injury [2, 12]. Toxic oxygen metabolites can be generated from many sources, including neutrophils, alveolar macrophages, endothelial cells, and lung parenchymal cells [3, 5, 9, 20, 21]. Previous work from this laboratory demonstrated that a non-neutrophil source of toxic oxygen metabolites was responsible for a significant portion of pulmonary ischemic–reperfusion injury. The injury could be readily produced in the absence of circulating blood elements and the addition of neutrophils did not augment the injury [10].

We hypothesized that the toxic oxygen metabolites causing the lung injury were generated during the metabolism of purine degradation products by xanthine oxidase. Xanthine oxidase is formed from xanthine dehydrogenase, by the action of proteases during ischemia [12]. Like xanthine dehydrogenase, xanthine oxidase metabolizes hypoxanthine initially to xanthine and then to uric acid. Unlike xanthine dehydrogenase, however, xanthine oxidase uses O2 as its electron acceptor, generating superoxide anion and hydrogen peroxide during this process [13]. These oxygen metabolites can be further metabolized into other species, including the highly toxic hydroxyl radical [13, 16, 18, 21]. To test the hypothesis that me-
tabolism of purine degradation products by xanthine oxidase was responsible for the ischemic-reperfusion injury, we administered lodoxamide, an inhibitor of xanthine oxidase, to evaluate its efficacy in attenuating lung injury.

MATERIALS AND METHODS

Ex vivo lung preparation. An ex vivo model was used to assess reperfusion lung injury after an ischemic insult. Lungs were isolated from male Long Evans rats (175–300 g) which had been anesthetized with pentobarbital (40 mg/kg intraperitoneally). The lungs were isolated and perfused at a constant flow of 0.03 ml/g rat body wt/min as previously described [14, 15]. Mean pulmonary artery inflow pressure was measured with a Statham transducer and recorded on a Grass recorder. Left atrial pressure (pulmonary outflow) was set by adjusting the height of the outflow reservoir. Except where specified, left atrial pressure was 0 mm Hg. The lungs were ventilated at 9 cm of water pressure with a positive-end expiratory pressure of 1 cm of water via a tracheal cannula with an air/gas mixture containing 21% O₂ and 5% CO₂ at a rate of 60 strokes/min, using a Harvard animal respirator. Lungs were perfused with physiologic salt solution (PSS) osmotically stabilized with Ficoll (4 g/100 ml) at 37°C. The first 25 ml of pulmonary venous effluent was discarded to eliminate rat blood elements from the lung vasculature. The final 2 ml of pulmonary venous effluent (blood-free) was collected prior to the onset of the ischemic period for the measurement of uric acid.

Lung reperfusion. Lungs were reperfused with heparinized homologous blood at 37°C. Reperfusion after ischemia was started slowly and the flow rate was increased such that a pressure greater than 30 mm Hg was never exceeded. The first 2 ml of pulmonary venous effluent (blood-free) was collected and assayed for uric acid produced during ischemia. Within 10 min of the onset of reperfusion the flow rate was increased to the same flow rate used prior to ischemia. Lungs were perfused for 30 min to reach a stable perfusion pressure and temperature prior to adding 125I-bovine serum albumin (125I-BSA) to the blood perfusate for the assessment of lung injury (described below). Simultaneously with the onset of reperfusion, lung ventilation was resumed with a gas mixture containing 21% O₂ and 5% CO₂.

Experimental groups. Three experimental groups were studied. The first group of five animals underwent 120 min of ischemia followed by reperfusion (ISCH). In the second group (of five animals) the same protocol was followed with the exception that lodoxamide (UpJohn Corp., Kalamazoo, MI), at a concentration of 1 mM, was added to all pre- and postischemic solutions (ISCH/LODOX). A third group of four nonischemit controls (CONT) consisted of lungs harvested and flushed with PSS/Ficoll in an identical manner, and then perfused with homologous whole blood at 37°C for 120 (n = 1) or 150 (n = 3) min prior to adding 125I-BSA to the blood perfusate. Perfusion and ventilation were never interrupted in the nonischemic control group. The perfusion time of 150 min was equal to the length of time the ischemic lungs were ex vivo before 125I-BSA was added to assay for lung injury.

Measurement of lung injury. Lung injury was assessed after 30 min of normothermic reperfusion (ISCH and ISCH/LODOX) or at the end of the 150-min control period (CONT). Lung injury was measured by the accumulation of 125I-BSA in lung parenchyma and alveolar lavage fluid over the 30 min period following the addition of 125I-BSA to the lung perfusate. Three measurements were performed to assay lung injury:
(a) the amount of $^{125}$I-BSA that accumulated in lung parenchyma, (b) the amount of $^{125}$I-BSA that accumulated in alveolar lavage fluid, and (c) the ratio of wet lung weight to rat body weight.

$^{125}$I-BSA was prepared by the standard chloramine T method. Unbound iodine was removed by gel filtration using a G-75 column. At the same time that $^{125}$I-BSA was added to the lung perfusate, the reservoir draining the pulmonary venous effluent was raised 8 cm above the level of the left atrium. The reservoir height was changed because small increases in left atrial pressure should markedly increase lung water and accumulation of $^{125}$I-BSA in lungs with increased vascular permeability (ischemic), but cause only small changes in lungs with normal vascular permeability (nonischemic). Thus, lungs with increased vascular permeability would be more easily identified. Once elevated, the reservoir remained elevated for the remainder of the experiment. Thirty minutes after the addition of $^{125}$I-BSA, 1 ml of pulmonary venous effluent was obtained, weighed, and counted for 2 min in a gamma scintillation counter. This allowed the determination of the number of $^{125}$I-BSA counts in 1.0 g of circulating perfusate.

The reservoir supplying perfusate to the lung was then clamped and a reservoir containing PSS osmotically stabilized with Ficoll (4 g/100 ml) was used to perfuse the lung at the same rate used throughout the experiment. After perfusion with 25 ml of this solution (containing no $^{125}$I-BSA) 1.0 ml of pulmonary venous effluent was obtained, weighed, and counted for 2 min in a gamma scintillation counter. This allowed the determination of the number of $^{125}$I-BSA counts in 1.0 g of circulating perfusate.

Electron microscopy. Transmission electron microscopy was performed to survey the ultrastructural pattern of lung injury that was produced and to determine whether or not the damage was altered by lodoxamide. Electron microscopy was performed in lungs subjected to 30 min of reperfusion following 120 min of ischemia at 37°C, with 1 mM lodoxamide present or absent in the blood perfusate. The lung was fixed with glutaraldehyde via tracheal instillation (at 15 cm H$_2$O) and then processed for light and electron microscopy [20].

Uric acid analysis. Uric acid was measured in the lung effluent. Timed collections of 2 ml each were placed in prechilled tubes. Samples were centrifuged at 5000g for 10 min at 4°C to remove cellular debris, and stored at -70°C until assayed. The concentrations of uric acid were determined by high-pressure liquid chromatography as previously described [6]. A liquid chromatograph system was used with a Waters Micro Bondapak C-18 10-µm particle-sized column (3.9 mm × 30 cm). The column was eluted with acetonitrile at a flow rate of 1.5 ml/min. The absorbance of the column effluent was monitored at 254 nm.

Statistics. Values were expressed as mean ± SEM. Groups were compared using one-way analysis of variance and the Newman-
TABLE 1

PROTECTIVE EFFECTS OF LODOXAMIDE IN LUNG ISCHEMIC-REPERFUSION INJURY [Lodoxamide] = 1 mM

<table>
<thead>
<tr>
<th>Groups</th>
<th>Albumin leak indices</th>
<th>Wet lung to rat body wt ratio</th>
<th>Peak PA pressure postischemia (mm Hg)</th>
<th>Mean PA pressure during 125I-BSA accumulation (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lung parenchyma</td>
<td>Alveolar lavage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONT</td>
<td>0.17 ± 0.04&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.006 ± 0.001&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5.1 ± 0.48&lt;sup&gt;d&lt;/sup&gt;</td>
<td>10 ± 1&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>ISCH</td>
<td>0.91 ± 0.15</td>
<td>0.156 ± 0.29</td>
<td>19 ± 2.84</td>
<td>20 ± 2</td>
</tr>
<tr>
<td>ISCH/LODOX</td>
<td>0.35 ± 0.05&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.029 ± 0.003&lt;sup&gt;d&lt;/sup&gt;</td>
<td>10.4 ± 0.83&lt;sup&gt;d&lt;/sup&gt;</td>
<td>17 ± 1&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> These groups are described under Materials and Methods.
<sup>b</sup> PA pressure was measured in all groups at a flow of 0.03 ml/g rat body wt/min.
<sup>c</sup> Peak pressure reached in the absence of an ischemic insult.
<sup>d</sup> P < 0.05 compared to ISCH.
<sup>e</sup> P < 0.06 compared to ISCH.

Keuls multiple comparison test. A P value less than 0.05 was accepted as significant.

RESULTS

Within 10 min of the onset of reperfusion the blood flow rate was increased to the same flow rate used prior to ischemia. At the same time that this flow rate (0.03 ml/g rat body wt/min) was achieved, mean pulmonary artery pressure (PA) was maximal in lungs subjected to the ischemic insult (Table 1). The corresponding PA pressure in control lungs (not subjected to an ischemic insult) was significantly lower (Table 1). Mean pulmonary artery pressure in the ischemic lungs then decreased toward baseline during the next 10 min of perfusion. At the end of this 10-min period the PA pressure was 16 ± 2 mm Hg which was significantly greater than pressure in the control lungs (8 ± 0.2 mm Hg). PA pressure then remained stable.

Significant lung injury occurred during the reperfusion of lungs subjected to the ischemic insult. There was increased accumulation of 125I-BSA in lung parenchyma and alveolar lavage fluid compared to the nonischemic control lungs as summarized in Table 1. Lung water was also increased as determined by an increase in lung wet weight to rat body weight in lungs reperfused following an ischemic insult. Lung injury was also evident by ultrastructural changes during reperfusion following the ischemic insult (Fig. 1). Endothelial and epithelial injury as well as alveolar hemorrhage were evident.

PA pressure at the time full flow was reached during reperfusion was lower in lungs treated with lodoxamide but still greater than in the control lungs (Table 1). However, PA pressure 10 min later (12 ± 1 mm Hg) was not different either from the ischemic lungs treated with lodoxamide or from the control lungs. The elevation in lung wet weight to rat body weight and increased accumulation of 125I-BSA in lung parenchyma and alveolar lavage fluid were also attenuated by lodoxamide. Lodoxamide also markedly attenuated the endothelial and epithelial cell injury. Alveolar hemorrhage was not seen (Fig. 1).

The alterations in accumulation of 125I-BSA in lung parenchyma and alveolar lavage fluid could have been due in part to changes in hydrostatic pressure as well as alterations in permeability secondary to endothelial and epithelial injury. Although the PA pressures during the period of 125I-BSA accumulation were different in the control lungs and in lungs subjected to an ischemic insult in the presence or absence of lodoxamide (Table 1), the differences in pressure were small. To evaluate this issue in more detail, lung albumin accumulation was compared in a subset of lungs from each of these groups (ISCH vs ISCH/LODOX). Lungs were paired such
that mean PA pressures during the period of $^{125}$I-BSA accumulation were not significantly different ($\leq 1$ mm Hg difference). In comparing these groups (paired t tests, $n = 3$) we observed that lungs in the ISCH/LODOX group lungs still had less ($P < 0.05$) $^{125}$I-BSA accumulation in lung parenchyma (0.42 $\pm$ 0.04) and alveolar lavage fluid (0.034 $\pm$ 0.003), when compared to lungs in the ISCH group (1.11 $\pm$ 0.16, 0.193 $\pm$ 0.033).

Uric acid levels. Uric acid was not detected in any perfusates preischemia. Postischemia, uric acid levels in the ISCH group were 38.8 $\pm$ 5.7 $\mu$M. In the ISCH/LODOX group, postischemic uric acid levels decreased to 20.9 $\pm$ 4.5 $\mu$M, a statistically significant decrease (Table 2).

### DISCUSSION

Our results suggest that the enzyme xanthine oxidase participates in ischemic–reperfusion lung injury. Lodoxamide, an inhibitor of xanthine oxidase [22], significantly attenuated ischemic–reperfusion injury. This was manifested by decreased pulmonary vascular resistance as well as decreased albumin accumulation in the lung parenchyma and alveolar space. In addition, electron microscopic examination of tissue samples showed that

### TABLE 2

<table>
<thead>
<tr>
<th>Groups</th>
<th>Uric acid level ($\mu$M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISCH (Preischemia)</td>
<td>0</td>
</tr>
<tr>
<td>ISCH (Postischemia)</td>
<td>38.8 $\pm$ 5.7</td>
</tr>
<tr>
<td>ISCH/LODOX (Preischemia)</td>
<td>0</td>
</tr>
<tr>
<td>ISCH/LODOX (Postischemia)</td>
<td>20.9 $\pm$ 4.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> $P < 0.05$ compared to ISCH.
the severe endothelial and epithelial injury in the ISCH group was markedly attenuated in the ISCH/LODOX perfused lungs. To document that lodoxamide inhibited xanthine oxidase, uric acid levels were measured, demonstrating that we had successfully achieved at least partial inhibition of the enzyme.

Other investigators have implicated xanthine oxidase in ischemic heart and intestinal injury [1, 12, 16, 17]. Attenuation of pulmonary injury using lodoxamide in our study coupled with the decrease in uric acid production is strong evidence that the xanthine oxidase hypothesis can now be extended to ischemic-reperfusion injury in the rat lung. We acknowledge, however, that alternative means of inhibiting xanthine oxidase will be required to verify this conclusion.

It is likely that the mechanism of xanthine oxidase injury is through generation of toxic oxygen metabolites [2, 12]. During ischemia, xanthine dehydrogenase is converted to xanthine oxidase which uses molecular oxygen as its electron acceptor, leading to the generation of hydrogen peroxide and superoxide anion [12], toxic oxygen species that can be further metabolized to the highly reactive hydroxyl radical [11–13]. Ischemia also precipitates a cascade of purine nucleotide breakdown which supplies substrates for xanthine oxidase [4]. Although we have shown that xanthine oxidase plays a role in ischemic reperfusion injury, it is probably not the sole source of injury as protection from injury was not complete. Alternatively, lodoxamide inhibition of xanthine oxidase may not have been complete. It is likely that many mechanisms contribute to this injury, although we have recently shown that neutrophils are not a factor in this model [10].

We speculate that oxygen radicals increased vascular permeability and alveolar leakage of protein by damaging lung endothelial and epithelial cells [19, 20]. As demonstrated in the electron micrographs (Fig. 1), destruction of alvoclar architecture was prominent in the ISCH example, whereas the ISCH/LODOX example was characterized by nearly normal architecture. Thus, the anatomic findings also support the possibility, based on 125I-BSA accumulation and gravimetric measurements, that oxygen radicals alter vascular permeability. Pulmonary artery pressures during 125I-BSA accumulation were slightly higher in the ISCH and CONT groups than in the ISCH/LODOX group, suggesting that differences in hydrostatic pressures could have accounted for the elevated accumulation of 125I-BSA rather than damage to endothelial and epithelial cells. However, when data from the ISCH/LODOX group were compared with those from the ISCH group at equivalent PA pressures, the leak indices were still dramatically different. Therefore, it is unlikely that differences in lung injury measurements can be explained by changes in hydrostatic pressures.

Ischemic-reperfusion lung injury is a factor limiting the usefulness of distant organ procurement for heart–lung transplantation [7]. If the mechanisms causing this injury were known then specific interventions might be developed to prevent the injury. Our findings suggest that the use of xanthine oxidase inhibitors may be one such intervention. Although the use of an isolated rat lung model allows identification of specific mechanisms, extension of these findings to intact animals must be done with caution. Species variability in purine biochemistry [6, 8] and the role of mechanical factors such as lung size must be examined to determine the relevance of our findings to human transplantation.

ACKNOWLEDGMENTS

Supported in part by Clinical Investigator Awards from the NIH, HL 01595 (MLM) and HL 01930 (CMG); The American Heart Association; the American Lung Association; and the Fellowship from The American Heart Association of Michigan.

REFERENCES